Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Hearing Loss, Idiopathic Sudden Sensorineural Clinical Trial

— ASSENT  

Official title:

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02809118
• Other study ID #: AM-111-CL-15-01
• Status: Terminated
• Phase: Phase 3
• Start date: June 2016
• Est. completion date: February 2018

Study information

• Verified date: June 2020
• Source: Auris Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the trial is the confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL).

Description:

This is a Phase III, randomized, double-blind, placebo-controlled, parallel group, multi-center, efficacy and safety trial of AM-111 in the treatment of subjects suffering from severe to profound idiopathic sudden sensorineural hearing loss.

The active pharmaceutical ingredient of AM-111 is a JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand.

The study consists of one treatment visit and a follow-up period until day 91.

Study participants will receive, after topical anesthesia of the tympanic membrane, AM-111 0.4 mg/mL or 0.8 mg/mL or placebo, administered into the affected ear. Following the administration, subjects will rest in a supine or reclined position for 30 minutes. Study participants will have the option for a course of oral corticosteroids.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 56
• Est. completion date: February 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Unilateral idiopathic sudden sensorineural hearing loss (ISSNHL) with onset within 72 hours prior to study treatment;

2. Mean hearing threshold of equal to or worse than (=) 60 dB averaged across those 3 contiguous air conduction audiometric pure tone frequencies that show the highest mean hearing loss compared with the unaffected contralateral ear or, in case of history of asymmetric hearing, corresponding values from a pre-existing audiogram for the affected ear not older than 2 years prior to the ISSNHL incident (defined as "pure tone average", PTA);

3. Mean hearing loss of equal to or worse than (=) 40 dB averaged across the air conduction thresholds at the pure tone average frequencies compared with the unaffected contralateral ear or, in case of history of asymmetric hearing, corresponding values from a preexisting audiogram for the affected ear not older than 2 years prior to the ISSNHL incident;

4. Age = 18 years on the day of screening;

Exclusion Criteria:

1. Bilateral ISSNHL;

2. Acute hearing loss from noise trauma, barotrauma or head trauma;

3. Air-bone gap greater than 20 dB at the average of 3 contiguous test frequencies below 4 kHz, when the air-bone gap is measurable;

4. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in either ear;

5. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;

6. Current evidence or history of acoustic neuroma or other retrocochlear damage in the affected ear;

7. History of otosclerosis in the affected ear;

8. Suspected perilymph fistula or membrane rupture in the affected ear;

9. Congenital hearing loss;

10. History of ISSNHL in the past 2 years;

11. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;

Related Conditions & MeSH terms

• Deafness
• Hearing Loss
• Hearing Loss, Idiopathic Sudden Sensorineural
• Hearing Loss, Sensorineural

Intervention

Drug:
• AM-111 0.4 mg/ml
AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
• AM-111 0.8 mg/ml
AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia

Other:
• Placebo
Placebo gel is administered with a single dose into the affected ear after topical anesthesia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Auris Medical, Inc.

Countries where clinical trial is conducted

United States,  Canada,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pure Tone Average (PTA)	Measurement of the recovery of hearing between Day 0 (before treatment) and Day 91, i.e. change in pure tone audiometry between Day 0 and Day 91. The study was prematurely terminated. It was pre-specified not to complete analyses due to premature termination. Not all data planned were collected. No meaningful efficacy analysis could be performed on the data.	Day 0 and Day 91: The study was prematurely terminated.
Secondary	Word Recognition Score (WRS) - Main Secondary	Change in WRS from Day 0 to Day 91. The WRS was determined with country-/language-specific word lists. At least 20 mono- or disyllabic words were presented in random order. After each word was presented to the subject, the subject was asked to repeat it, and to guess it, if he/she was not sure of the word. The study was prematurely terminated. It was pre-specified not to complete analyses due to premature termination. Not all data planned were collected. No meaningful efficacy analysis could be performed on the data.	Day 0 and Day 91: The study was prematurely terminated.

External Links

•   Study webpage with information on study and sites participating